Scalper1 News
Specialty drugmaker Allergan raised its guidance Thursday and took the opportunity to say yet again that Valeant Pharmaceuticals’ hostile bid for the company was too low. Allergan (AGN) stock nonetheless was flat in morning trading on the stock market today, near 190. Allergan’s Q3 earnings guidance is now $1.76 to $1.78 a share, more than 20 cents higher than the firm’s previous guidance and analysts’ consensus of $1.48. Allergan says that Scalper1 News
Scalper1 News